STAG2

Across TCGA pan-cancer cohorts, STAG2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STAG2 data layer compared with 25 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher STAG2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STAG2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

UCEC, HNSC, and LUAD are the cancer types where STAG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	II,III,IV	0.529	1.000	.008	16	view →
HNSC	OS	Tertile	All	0.746	0.894	.005	14	view →
LUAD	OS	Quartile	III,IV	0.861	0.266	.005	10	view →
PDAC	DFS	Quartile	II,III,IV	0.346	0.587	.034	4	view →
LSCC	OS	Median	All	0.876	0.712	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STAG2–UCEC (DFS)

Open the UCEC breakdown →